Skip to content

Reactivation of Varicella Zoster Virus and Risk of Vascular Disease

Reactivation of Varicella Zoster Virus and Risk of Vascular Disease in the Health Survey for England: a Nested Case Control Study

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02559596
Enrollment
0
Registered
2015-09-24
Start date
2015-06-30
Completion date
2019-01-31
Last updated
2019-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction, Stroke, Transient Ischaemic Attack, Varicella Zoster

Brief summary

The purpose of this study is to investigate whether there is an association between stroke or heart attack and reactivation of varicella zoster virus, measured by antibody levels, using linked data from the Health Survey for England and secondary care.

Detailed description

This study will use a case control design to investigate whether adult participants in the Health Survey for England between 2009 and 2013 who were admitted to hospital with either a stroke or heart attack had higher preceding levels of varicella zoster virus antibodies measured in stored serum samples compared to matched controls with no history of heart attack or stroke, controlling for a range of potential demographic, lifestyle and clinical confounders. This study is funded by the University College London Hospitals Biomedical Research Centre Fast Track grant scheme and has received ethics approval (ref 15/NW/0456).

Interventions

None listed

Sponsors

University College, London
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Previous participant in the HSE between 2009 and 2013 with stored serum available. * Either a record of stroke or TIA or MI in linked HES data between 01/01/2009 and 31/12/2013 or selected as a matched control for those with a record of stroke/ TIA/MI in HES data. * Male or female, aged 16 years or above.

Exclusion criteria

* HSE participant with no stored serum sample

Design outcomes

Primary

MeasureTime frame
Odds ratio for the effect of high serum antibody titre on stroke or other vascular outcomesOutcome assessed within 5 years of serum sample

Secondary

MeasureTime frame
Prevalence of age- and sex-specific serum VZV antibody titres as a marker for virus reactivationAssessed at baseline recruitment to the HSE

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026